MTD119 is a combination of the company’s gold nanoparticle technology and the drug maytansine. It is being developed to tackle in a targeted way hepatocellular carcinoma, a rare, aggressive cancer that affects the liver and which has a poor prognosis
Original Article: Midatech Pharma wins orphan designation for liver cancer drug